These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 20637303

  • 1. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Blagborough AM, Yoshida S, Sattabongkot J, Tsuboi T, Sinden RE.
    Vaccine; 2010 Aug 23; 28(37):6014-20. PubMed ID: 20637303
    [Abstract] [Full Text] [Related]

  • 2. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T, Harakuni T, Sugawa H, Sattabongkot J, Kato A, Tachibana M, Torii M, Tsuboi T, Arakawa T.
    Vaccine; 2011 Mar 24; 29(15):2720-6. PubMed ID: 21315699
    [Abstract] [Full Text] [Related]

  • 3. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
    Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N, Rungruang T, Cao YM, Stowers AW, Sirichaisinthop J, Coleman RE, Torii M.
    Am J Trop Med Hyg; 2003 Nov 24; 69(5):536-41. PubMed ID: 14695092
    [Abstract] [Full Text] [Related]

  • 4. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A.
    Malar J; 2007 Aug 08; 6():107. PubMed ID: 17686163
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS, Mukherjee P, Yazdani SS, Shakri AR, Mazumdar S, Pandey S, Chitnis CE, Chauhan VS.
    Vaccine; 2007 Jul 09; 25(28):5166-74. PubMed ID: 17544179
    [Abstract] [Full Text] [Related]

  • 6. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes.
    Arakawa T, Tsuboi T, Kishimoto A, Sattabongkot J, Suwanabun N, Rungruang T, Matsumoto Y, Tsuji N, Hisaeda H, Stowers A, Shimabukuro I, Sato Y, Torii M.
    Vaccine; 2003 Jul 04; 21(23):3143-8. PubMed ID: 12804841
    [Abstract] [Full Text] [Related]

  • 7. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization.
    Miyata T, Harakuni T, Tsuboi T, Sattabongkot J, Kohama H, Tachibana M, Matsuzaki G, Torii M, Arakawa T.
    Infect Immun; 2010 Sep 04; 78(9):3773-82. PubMed ID: 20584978
    [Abstract] [Full Text] [Related]

  • 8. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
    Kongkasuriyachai D, Bartels-Andrews L, Stowers A, Collins WE, Sullivan J, Sattabongkot J, Torii M, Tsuboi T, Kumar N.
    Vaccine; 2004 Aug 13; 22(23-24):3205-13. PubMed ID: 15297075
    [Abstract] [Full Text] [Related]

  • 9. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
    Ramjanee S, Robertson JS, Franke-Fayard B, Sinha R, Waters AP, Janse CJ, Wu Y, Blagborough AM, Saul A, Sinden RE.
    Vaccine; 2007 Jan 15; 25(5):886-94. PubMed ID: 17049690
    [Abstract] [Full Text] [Related]

  • 10. The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice.
    Kim TS, Kim HH, Moon SU, Lee SS, Shin EH, Oh CM, Kang YJ, Kim DK, Sohn Y, Kim H, Lee HW.
    Exp Parasitol; 2011 Feb 15; 127(2):346-50. PubMed ID: 20801117
    [Abstract] [Full Text] [Related]

  • 11. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T, Komesu A, Otsuki H, Sattabongkot J, Udomsangpetch R, Matsumoto Y, Tsuji N, Wu Y, Torii M, Tsuboi T.
    Infect Immun; 2005 Nov 15; 73(11):7375-80. PubMed ID: 16239536
    [Abstract] [Full Text] [Related]

  • 12. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.
    Arévalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincón A, Saul A, Mu J, Long C, Miller L, Herrera S.
    Am J Trop Med Hyg; 2005 Nov 15; 73(5 Suppl):32-7. PubMed ID: 16291764
    [Abstract] [Full Text] [Related]

  • 13. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen.
    Mlambo G, Kumar N, Yoshida S.
    Vaccine; 2010 Oct 08; 28(43):7025-9. PubMed ID: 20709008
    [Abstract] [Full Text] [Related]

  • 14. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M, Sato C, Otsuki H, Sattabongkot J, Kaneko O, Torii M, Tsuboi T.
    Vaccine; 2012 Feb 27; 30(10):1807-12. PubMed ID: 22245309
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Cao Y, Hayashi CTH, Araujo MDS, Tripathi AK, Andrade AO, Medeiros JF, Vinetz J, Kumar N.
    Vaccine; 2024 Aug 30; 42(21):126140. PubMed ID: 39033079
    [Abstract] [Full Text] [Related]

  • 16. A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice.
    Gentil F, Bargieri DY, Leite JA, Françoso KS, Patricio MB, Espíndola NM, Vaz AJ, Palatnik-de-Sousa CB, Rodrigues MM, Costa FT, Soares IS.
    Vaccine; 2010 Aug 31; 28(38):6183-90. PubMed ID: 20654667
    [Abstract] [Full Text] [Related]

  • 17. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.
    Mizutani M, Iyori M, Blagborough AM, Fukumoto S, Funatsu T, Sinden RE, Yoshida S.
    Infect Immun; 2014 Oct 31; 82(10):4348-57. PubMed ID: 25092912
    [Abstract] [Full Text] [Related]

  • 18. Preparation, crystallization and preliminary X-ray analysis of a complex between the Plasmodium vivax sexual stage 25 kDa protein Pvs25 and a malaria transmission-blocking antibody Fab fragment.
    Saxena AK, Singh K, Long CA, Garboczi DN.
    Acta Crystallogr D Biol Crystallogr; 2004 Nov 31; 60(Pt 11):2054-7. PubMed ID: 15502325
    [Abstract] [Full Text] [Related]

  • 19. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Blagborough AM, Musiychuk K, Bi H, Jones RM, Chichester JA, Streatfield S, Sala KA, Zakutansky SE, Upton LM, Sinden RE, Brian I, Biswas S, Sattabonkot J, Yusibov V.
    Vaccine; 2016 Jun 14; 34(28):3252-9. PubMed ID: 27177945
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.